Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2022 08:00 ET | Source: Cabaletta Bio

U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART

– Fast Track Designation granted to improve activities of daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis – PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE)...
February 28, 2022 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference

PHILADELPHIA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
January 11, 2022 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer

PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
January 10, 2022 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
January 03, 2022 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Conference

PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
December 14, 2021 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris

PHILADELPHIA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
November 09, 2021 16:30 ET | Source: Cabaletta Bio

Cabaletta Bio to Participate in Upcoming Investor Conferences in November

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
November 09, 2021 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
November 01, 2021 07:05 ET | Source: Cabaletta Bio

Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update

– Dose dependent increase in DSG3-CAART persistence observed in the third dose cohort with 500 million DSG3-CAART cells relative to the first two low dose cohorts in DesCAARTes™ Phase 1 clinical trial...
November 01, 2021 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV

– Dose dependent increase in DSG3-CAART persistence observed in the third dose cohort relative to the first two low dose cohorts throughout the 28 days following infusion – – No dose-limiting...